The data represents a significant derisking catalyst for AN2-502998, a potential first-in-class oral treatment for a large unmet need market. Monitor for initiation of the Phase 2 study late 2026 and any partnership or financing announcements. The stock may re-rate on the NHP efficacy and safety profile, but binary clinical risk remains.
Price Chart
Executive Summary
AN2 Therapeutics reported positive enabling data for its oral CPSF3 inhibitor AN2-502998 in chronic Chagas disease. A 28-day NHP study achieved 100% parasite elimination at human-attainable exposures, durable through 4 months post-treatment, and the Phase 1 FIH study showed a favorable safety profile with no dose-limiting toxicities. The company plans to initiate a Phase 2 study late 2026 and highlights a multi-billion-dollar global market opportunity with potential FDA Priority Review Voucher eligibility.
Key Facts
- 100% of treated NHPs achieved parasite elimination at target exposures attainable in humans after 28 days of AN2-502998.
- Parasite elimination was durable and maintained through 4 months following end of treatment.
- Phase 1 FIH study showed AN2-502998 was generally well tolerated with no dose-limiting toxicities; human PK at or above NHP efficacy thresholds.
- AN2-502998 is the only compound to have demonstrated curative activity in NHPs with naturally acquired chronic T. cruzi infection.
- No FDA-approved treatments exist for adults with chronic Chagas disease; over 300,000 infected in the U.S., ~10M globally.
- Company plans to initiate a Phase 2 proof-of-concept study late 2026 in collaboration with DNDi.
- Potential multi-billion-dollar market opportunity and eligibility for FDA Tropical Disease Priority Review Voucher.
Financial Impact
No financial figures provided; company highlights a potential multi-billion-dollar global market opportunity for Chagas disease, but no actual revenue, EPS, or deal values are disclosed.
Risk Factors
- Preclinical NHP data may not predict human trial outcomes; Phase 2 proof-of-concept results expected late 2026 or later.
- Company will need additional capital to fund Phase 2 and beyond; dilution risk remains.
- Regulatory path for Chagas disease is undefined; no FDA-approved adult treatment exists, creating precedent uncertainty.
- Commercial opportunity is based on company estimates and market analogy to hepatitis C, which may not materialize.
Market Snapshot
Investment Themes
Documents Analyzed
This report is based on 5 SEC documents filed with EDGAR.
| Document | Accession Number |
|---|---|
| 8-K Filing (Primary) | 0001193125-26-257430 |
| Document: d247428dex991.htm | 0001193125-26-257430 |
| Document: 0001193125-26-257430-index-headers.html | 0001193125-26-257430 |
| Document: 0001193125-26-257430-index.html | 0001193125-26-257430 |
| Document: 0001193125-26-257430.txt | 0001193125-26-257430 |
Track record builds as more directional reports settle.
Filters
| Type | Now | ||||
|---|---|---|---|---|---|
Aug 11, 2026 10w ago | 8-K | $6.28 | awaiting T+60 | — | $3.63 (−42.20%) |
Jun 4, 2026 20w ago | 8-K | $3.82 $5.55 | ▲ +45.29% | ▲ +41.29% | $3.63 (−4.97%) |
Apr 22, 2026 26w ago | DEFA14A | $4.28 $4.80 | ▲ +12.15% | ▲ +7.13% | $3.63 (−15.19%) |
Apr 21, 2026 26w ago | EFFECT | $3.80 $4.67 | ▲ +22.89% | ▲ +16.00% | $3.63 (−4.47%) |
Apr 20, 2026 27w ago | 424B5 | $3.80 $4.67 | ▼ −22.89% | ▼ −16.00% | $3.63 (+4.47%) |
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers